000627，主动退市！

Core Viewpoint - *ST Tianmao plans to voluntarily delist its A-shares from the Shenzhen Stock Exchange due to difficulties in disclosing its annual report and will apply for transfer to the delisting board managed by the National Equities Exchange and Quotations after the delisting [2][4] Group 1: Delisting Process - On August 8, *ST Tianmao first announced its intention to voluntarily delist its A-shares from the Shenzhen Stock Exchange [4] - The delisting proposal was approved at the company's first extraordinary general meeting in 2025 on August 25, and the company submitted the delisting application to the Shenzhen Stock Exchange [4] - After delisting, *ST Tianmao aims to maintain stable operations and protect shareholders' legal rights, with no plans for major asset restructuring or specific timelines for re-listing [4] Group 2: Reporting Issues - *ST Tianmao failed to disclose its 2024 annual report and the first quarter report for 2025 within the legal timeframe, leading to a delisting risk warning on July 8, 2025 [4][5] - If the company does not disclose more than half of the board's assurance of the 2024 annual report within two months of the delisting risk warning, the Shenzhen Stock Exchange will decide to terminate the company's stock listing [4] Group 3: Company Background - *ST Tianmao was publicly listed in 1996 and underwent a significant change in ownership in 2002 when Liu Yiqian became the actual controller after acquiring the company [5] - The company transitioned from a pharmaceutical focus to the insurance industry, primarily operating through its subsidiaries, Guohua Life and Huarui Insurance [5] - As of August 13, the last trading day, *ST Tianmao's stock price was 1.58 yuan per share, with a total market capitalization of 7.7 billion yuan [5]